<div id="readability-page-1">Seaport Therapeutics (SPTX), a Boston-based biotech developing drugs to treat major depression, increased its IPO’s size at pricing – to 14.16 million shares – up from 11.8 million in the prospectus – and priced its IPO at $18.00 – the top of its range – to raise $254.88 million on Thursday night, April 30, 2026. Shares of Seaport Therapeutics are set to start trading today – Friday, May 1, 2026 – on the NASDAQ. Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup and Stifel are the joint book-runners. At pricing, Seaport Therapeutics had a market cap of $954.5 million. Seaport Therapeutics (SPTX) intends to use the IPO’s proceeds to help fund the Phase 2 clinical trials of its leading drug candidates, GlyphAllo (SPT-300) and GlyphAgo (SPT-320), to treat major depression, including postpartum depression. The company is not profitable. (For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.) Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board. To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message. Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.</div>

SEELQ

SEEL

生物科技 ETF - VanEck Vectors

Seaport Therapeutics（SPTX），一家位於波士頓的生物科技公司，已將其首次公開募股（IPO）規模增加至 1416 萬股，定價為 18.00 美元，籌集資金為 2.5488 億美元。該股票將於 2026 年 5 月 1 日在納斯達克交易。公司計劃將籌集的資金用於其治療重度抑鬱症藥物的第二階段臨牀試驗。按此定價，Seaport Therapeutics 的市值為 9.545 億美元。高盛等公司是此次 IPO 的聯合主承銷商

The IPO Buzz: Seaport Therapeutics Increases IPO’s Size & Prices it at $18 – Top of Range

IPO Scoop

SEELOS THERAPEUTICS INC

Seelos Therapeutics

納斯達克生物科技指數 ETF - iShares Nasdaq

紐交所高增長板生物技術指數 ETF - First Trust

Invesco Nasdaq Biotechnology ETF

醫藥突破 ETF - ALPS

2 倍做多納斯達克生物技術 ETF - ProShares

動態生物技術與基因組 ETF - Invesco

基因改革 ETF - ARK

標普生物技術 3 倍做多 - Direxion

標普生物技術 ETF - SPDR

高盛

摩根大通

花旗

Stifel Financial

納斯達克 OMX 交易所

GS Hldg R

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

首次公開募股動態：Seaport Therapeutics 增加了 IPO 的規模，並將其定價為 18 美元——處於定價區間的高端